The positive efficacy of dexmedetomidine on the clinical outcomes of patients undergoing renal transplantation: evidence from meta-analysis DOI Creative Commons
Shanshan Guo, Degong Jia, Xueqi Liu

et al.

Aging, Journal Year: 2023, Volume and Issue: 15(23), P. 14192 - 14209

Published: Dec. 11, 2023

Introduction: Whether dexmedetomidine (DEX), an anesthetic adjuvant, can improve renal transplant outcomes is not clear. Methods: We systematically identified clinical trials in which DEX was administered transplantation (RT). On November 1, 2022, we searched The Cochrane Library, MEDLINE, EMBASE and https://www.clinicaltrials.gov/. main were delayed graft function acute rejection. Results: A total of seven studies included the meta-analysis. results showed that compared with control, significantly reduced occurrence (RR 0.76; 95% CI 0.60–0.98), short-term serum creatinine [postoperative day (POD) 2: (MD −22.82; −42.01 – −3.64)] blood urea nitrogen [POD −2.90; −5.10 −0.70); POD 3: 2.07; −4.12 −0.02)] levels, postoperative morphine consumption −4.27; −5.92 −2.61) length hospital stay −0.85; CI−1.47 −0.23). However, did reduce risk rejection 0.75; 0.45–1.23). subgroup analysis country type, donor average age had a certain impact on role DEX. Conclusions: may outcome RT shorten patients.

Language: Английский

Dexmedetomidine alleviates ferroptosis following hepatic ischemia-reperfusion injury by upregulating Nrf2/GPx4-dependent antioxidant responses DOI Open Access
Yongjun Zhang,

Hua Wei,

Mengmei Wang

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 169, P. 115915 - 115915

Published: Nov. 24, 2023

Hepatic ischemia-reperfusion injury (HIRI) adversely affects liver transplant and resection outcomes. Recently, ferroptosis has been associated with HIRI. Dexmedetomidine (Dex), a potent sedative anti-inflammatory, antioxidant, anti-apoptotic properties, protects organs from hypoxic or (I/R) injuries. However, the mechanisms underlying this protective effect against I/R-induced remain unclear. This study evaluated of Dex on HIRI in mouse models oxygen-glucose deprivation/reperfusion (OGD/R) AML12 cell model. We examined ferroptosis-related markers, including Fe2+ levels, reactive oxygen species (ROS) content, mitochondrial morphology, GPX4 protein expression, 4-hydroxynonenal (4-HNE), Nrf2. The Nrf2 inhibitor ML385 was used combination to treat mice OGD/R-induced cellular explore pathways by which counteracts ferroptosis. Our results showed that treatment significantly ameliorated cells, reduced Fe2+, ROS, malondialdehyde (MDA), 4-HNE levels. also tissue damage serum AST, ALT, inflammatory factor levels mice. Additionally, increased GSH, an antioxidative stress marker, expression Mechanistically, nuclear translocation were inhibited both OGD/R-treated cells. restored inhibition translocation. Dex-promoted aggregation Gpx4 hindering efficacy Dex. In conclusion, ameliorates positively regulating Nrf2/GPx4 axis, potentially presenting therapeutic avenue for addressing

Language: Английский

Citations

15
Identification of PANoptosis related biomarkers to predict hepatic ischemia‒reperfusion injury after liver transplantation DOI Creative Commons
Zhihong Chen, Junwei Zhang, Lei Zhang

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: May 2, 2025

Language: Английский

Citations

0
The positive efficacy of dexmedetomidine on the clinical outcomes of patients undergoing renal transplantation: evidence from meta-analysis DOI Creative Commons
Shanshan Guo, Degong Jia, Xueqi Liu

et al.

Aging, Journal Year: 2023, Volume and Issue: 15(23), P. 14192 - 14209

Published: Dec. 11, 2023

Introduction: Whether dexmedetomidine (DEX), an anesthetic adjuvant, can improve renal transplant outcomes is not clear. Methods: We systematically identified clinical trials in which DEX was administered transplantation (RT). On November 1, 2022, we searched The Cochrane Library, MEDLINE, EMBASE and https://www.clinicaltrials.gov/. main were delayed graft function acute rejection. Results: A total of seven studies included the meta-analysis. results showed that compared with control, significantly reduced occurrence (RR 0.76; 95% CI 0.60–0.98), short-term serum creatinine [postoperative day (POD) 2: (MD −22.82; −42.01 – −3.64)] blood urea nitrogen [POD −2.90; −5.10 −0.70); POD 3: 2.07; −4.12 −0.02)] levels, postoperative morphine consumption −4.27; −5.92 −2.61) length hospital stay −0.85; CI−1.47 −0.23). However, did reduce risk rejection 0.75; 0.45–1.23). subgroup analysis country type, donor average age had a certain impact on role DEX. Conclusions: may outcome RT shorten patients.

Language: Английский

Citations

0